CLL highly dependent on microenvironment.
BTK, a member of TEC kinase family.
Though BTK not expressed in T cells; it inhibits ITK, which is expressed in T cells. This reduces cytokine secretion without inducing apoptosis from activated T cells.
In 10 CLL patients treated with ibrutinib, effect on T-cell subsets, T-cell activation, and cytokine profiles assessed.
Cytokine levels pre-treatment and on days 1, 28, months 2, and 6 measured.
Serum levels of number of inflammatory cytokines decreased by > 50% by day 28 of ibrutinib treatment and remained so by 6 months.
j
Ibrutiib reduced frequency of activated CD4+ T cells.
Ibrutinib reduceS cytokine and chemokine secretion from both CLL and T cells.
Ibrutinib alters tumor microenvironment in CLL.
Ibrutinib : highly effective in blocking BCR signaling.
Impressive clinical responses in CLL.
The effects on tumor microenviroment may be important for clinical response.
View the original abstract on the ASH website.
